What to verify
- The exact chemical form and formulation.
- A lot-specific assay and identity result.
- Container-closure and stability documentation.
- Written handling conditions tied to that exact product.
Why trial evidence does not fill the gap
Clinical publications establish results for sponsor-controlled material. They do not publish a universal shelf-life or storage rule for unrelated third-party vials.
What this evidence review covers
Explain why storage is formulation-specific and why generic refrigeration/after-mixing rules are unsupported.
- Required stability evidence: identity, formulation, container, temperature, light, time, and assay
- Trial material versus vendor product
- Unopened versus prepared product are separate questions
- Why a 28-day rule is unsupported
- Use only verified product-specific documentation
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
source limitation
Peer-reviewed efficacy trials do not supply stability instructions for independent research-market products.
regulatory
Retatrutide is not an FDA-approved compounded-drug component under the inspected guidance.
| Evidence class | What the source supports |
|---|---|
| source limitation | Peer-reviewed efficacy trials do not supply stability instructions for independent research-market products. |
| regulatory | Retatrutide is not an FDA-approved compounded-drug component under the inspected guidance. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
Evidence class: primary randomized phase 2. What it supports: n=338 obesity/overweight trial; receptor description; dose arms; 24- and 48-week weight outcomes; reported adverse events.
What it does not establish: Approved use, long-term benefit-risk, vendor-product equivalence, cross-trial superiority, or a consumer protocol.
FDA concerns with unapproved GLP-1 drugs used for weight loss
Evidence class: primary regulatory. What it supports: Retatrutide and cagrilintide are not components of approved drugs, have not been found safe and effective, and cannot be used in compounding under federal law; FDA warnings about false research labels.
What it does not establish: A general claim that every observed listing is unlawful in every jurisdiction.
Questions this page answers
Does Retatrutide need refrigeration?
The answer must come from validated documentation for the exact formulation and container; no universal rule was established.
How long does it last after mixing?
Do not publish a generic time. Beyond-use claims require product-specific stability and microbiological evidence.
What remains unresolved
- No validated stability dossier for tracked vendor vials.
- No independent degradation or sterility study.
- Storage snippets from competitors are not authority.